Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2015

01-07-2015 | Review Article

Endometrial cancer: redefining the molecular-targeted approach

Authors: Jesse Lopes da Silva, Eduardo Paulino, Mariane Fontes Dias, Andréia Cristina de Melo

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2015

Login to get access

Abstract

Endometrial cancer (EC) is the most frequent gynecologic malignancy in the world. Metastatic and recurrent disease confers a worse prognosis, and the side effects of the current cytotoxic agents are the main cause of treatment disruption. Recently, the genetic alterations that facilitate the start, development and progression of EC have been elucidated, reclassifying the disease in distinct subtypes with different mechanisms of carcinogenesis. Targeted therapy aims to interfere specifically these mechanisms causing less toxicity, therefore opening new perspectives for a tailored treatment and improvement of response and survival rates for heavily treated recurrent disease. Treatment with hormone therapy was not addressed in this review because it is an extensively discussed issue and would divert the discussion about molecular-targeted therapy. The purpose of this paper was to review the available literature data regarding the main genetic abnormalities related to the carcinogenesis and evaluate the safety and efficacy of the molecular-targeted agents in the treatment of metastatic and recurrent EC.
Literature
1.
2.
Doll A, Abal M, Rigau M et al (2008) Novel molecular profiles of endometrial cancer new light through hold windows. J Steroid Biochem Mol Biol 108(3–5):221–229PubMedCrossRef
3.
4.
Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ (1995) Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 26:1260–1267PubMedCrossRef
5.
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67–73PubMedCrossRef
6.
7.
Hecht Jonathan L, Mutter George L (2006) Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24(29):4783–4791PubMedCrossRef
8.
Thoury A, Descatoire V, Kotelevets L, Kannengiesser C, Bertrand G, Theou-Anton N, Frey C, Genestie C, Raymond E, Chastre E, Lehy T, Walker F (2014) Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability. Histol Histopathol 29(11):1455–1466
9.
Heinen CD (2014) Translating mismatch repair mechanism into cancer care. Curr Drug Targ 15:53–64CrossRef
10.
Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD, Frank TS (1996) Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 148:1671–1678PubMedCentralPubMed
11.
Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG (1998) MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 17:2413–2417PubMedCrossRef
12.
Swisher EM, Mutch DG, Herzog TJ et al (1998) Analysis of MSH3 in endometrial cancers with defective DNA mismatch repair. J Soc Gynecol Investig 5:210–216PubMedCrossRef
13.
Bilbao C, Rodrıguez G, Ramırez R, Falcon O, Leon L, Chirino R, Rivero JF et al (2006) The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int J Cancer 119:563–570PubMedCrossRef
14.
Cohn DE, Basil JB, Venegoni AR et al (2000) Absence of PTEN repeat tract mutation in endome- microsatellite instability. Gynecol Oncol 79:101–106PubMedCrossRef
15.
Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558–561PubMedCrossRef
16.
Jernvall P, Makinen MJ, Karttunen TJ, Makela J, Vihko P (1999) Microsatellite instability impact on cancer progression in proximal and distal colorectal cancers. Eur J Cancer 35:197–201PubMedCrossRef
17.
Johannsdottir JT, Bergthorsson JT, Gretarsdottir S, Kristjans-son AK, Ragnarsson G, Jonasson JG et al (1999) Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. Anticancer Res 19:1821–1826PubMed
18.
Catasus L, Machin P, Matias-Guiu X, Prat J (1998) Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum Path 29:1160–1164PubMedCrossRef
19.
Miller D, Filiaci V, Fleming G et al (2012) Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 125:771–773CrossRef
20.
21.
Mutter GL, Lin MC et al (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Nat Can Inst 92:11CrossRef
22.
Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI et al (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57:3935–3940PubMed
23.
Risinger JI, Hayes AK, Berchuck A, Barrett JC (1997) PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57:4736–4738PubMed
24.
Pavlidou A, Vlahos NF (2014) Molecular Alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer. Sci World J, Art id 709736
25.
Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW (2011) PIK3R1 (p85a) is somatically mutated at high frequency in primary endometrial cancer. Can Resear 71(12):4061–4067CrossRef
26.
Cheung LW et al (2011) High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2:170–185CrossRef
27.
Slomovitz BM, Lu KH, Johnston T et al (2010) A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116(23):5415–5419PubMedCrossRef
28.
Kim DH, Sarbassov DD, Ali SM et al (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110(2):163–175PubMedCrossRef
29.
Shoji K, Oda K, Nakagawa S et al (2009) The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 101(1):145–148PubMedCentralPubMedCrossRef
30.
Swisher EM, Peiffer-Schneider S, Mutch DG et al (1999) Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer 85:119–126PubMedCrossRef
31.
Lax SF, Kendall B, Tashiro H et al (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88:814–824PubMedCrossRef
32.
Lagarda H et al (2001) K-ras mutations in endometrial carcinomas with microsatellite instability. J Path 193(2):193–199PubMedCrossRef
33.
34.
Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J (1998) Altered cadherin and catenin complexes in the Barrett’s esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 152(1):135–144PubMedCentralPubMed
35.
Wirtz R, Kuhl M, Wedlich D, Birchmeier W (1998) Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280:596–599PubMedCrossRef
36.
Kim YT, Choi EK, Kim JW et al (2002) Expression of E-cadherin and alpha-, beta-, gamma-catenin proteins in endometrial carcinoma. Yonsei Med J 43:701–711PubMedCrossRef
37.
Shih HC, Shiozawa T, Miyamoto T et al (2004) Immunohistochemical expression of E-cadherin and beta-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear beta-catenin expression. Anticancer Res 24:3843–3850PubMed
38.
39.
Oehler MK, Brand A, Wain GV (2003) Molecular genetics and endometrial cancer. J Br Menopause 3:27–31CrossRef
40.
Katoh M (2008) Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 33:233–237PubMed
41.
Byron SA, Gartside MG, Wellens CL et al (2008) Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 68:6902PubMedCrossRef
42.
43.
Gatius S, Velasco A, Azueta A, Santacana M et al (2011) FGFR2 alterations in endometrial carcinoma. Modern Path 24:1500–1510CrossRef
44.
Macdonald ND, Salvesen HB, Ryan A, Malatos S, Stefansson I, Iversen OE et al (2004) Molecular differences between RER + and RER- sporadic endometrial carcinomas in a large population-based series. Int J Gynecol Cancer 14:957–965PubMedCrossRef
45.
Risinger JI, Maxwell GL, Berchuck A, Barrett JC (2003) Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers. Ann N Y Acad Sci 983:208–212PubMedCrossRef
46.
Niederacher D, An HX, Cho YJ, Hantschmann P, Bender HG, Beckmann MW (1999) Mutations and amplification of oncogenes in endometrial cancer. Oncology 56:59–65PubMedCrossRef
47.
Saffari B, Jones LA, El-Naggar A, Felix JC, George J, Press MF (1995) Amplification and overexpression of HER-2/neu (c-erbB2) in endome- trial cancers: correlation with overall survival. Cancer Res 55:5693–5698PubMed
48.
Vasen HF, Watson P, Mecklin JP et al (1994) The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 14:1675–1678PubMed
49.
Peltomaki P, Vasen HF, The International Collaborative Group on HNPCC (1997) Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. Gastroenterology 113:1146–1158PubMedCrossRef
50.
Williams JA Jr, Wang ZR, Parrish RS, Hazlett LJ, Smith ST, Young SR (1999) Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer. Exp Mol Pathol 67:135–143PubMedCrossRef
51.
Chon HS, Hu W, Kavanagh JJ (2006) Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets 4:333–363CrossRef
52.
Miyaki M, Konishi M, Tanaka K et al (1997) Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 17:271–272PubMedCrossRef
53.
Schweizer P, Moisio AL, Kuismanen SA et al (2001) Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas in hereditary nonpolyposis colorectal cancer. Cancer Res 61:2813–2815PubMed
54.
Parc YR, Halling KC, Burgart LJ et al (2000) Microsatellite instability and hMLH1/hMSH2 expression in young endometrial carcinoma patients: association with family history and histopathology. Int J Cancer 86:60–66PubMedCrossRef
55.
De Leeuw WJ, Dierssen J, Vasen HF et al (2000) Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumors from HNPCC patients. J Pathol 192:328–335PubMedCrossRef
56.
57.
Ollikainen M, Abdel-Rahman WM, Moisio AL et al (2005) Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol 23:4609–4616PubMedCrossRef
58.
Aghajanian C, Sill MW, Darcy KM et al (2011) Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic oncology group study. J Clin Oncol 29:2259–2265PubMedCentralPubMedCrossRef
59.
National Cancer Institute (2000) Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in treating patients with stage III, Stage IV, or Recurrent Endometrial Cancer. Bethesda (MD): National Library of Medicine (US). http://​clinicaltrials.​gov/​show/​NCT00977574 NLM identifier: NCT 00977574
60.
Coleman RL, Sill MW, Lankes HA et al (2012) A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 127:538–543PubMedCentralPubMedCrossRef
61.
McMeekin DS, Sill MW, Benbrook D et al (2007) A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a gynecologic oncology group study. Gynecol Oncol 105:508–516PubMedCentralPubMedCrossRef
62.
Castonguay V, Lheureux S, Welch S, Mackay HJ et al (2014) A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol 134:274–280PubMedCrossRef
63.
Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A et al (2008) Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC-148. J Clin Oncol 26:4319–4432PubMedCrossRef
64.
Leslie KK, Sill MW, Darcy KM et al (2009) Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. J Clin Oncol 27:e16542
65.
Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S (2008) Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet 102(2):128–131PubMedCrossRef
66.
Jewell E, Secord AA, Brotherton T, Berchuck A (2006) Use of trastuzumab in the treatment of metastatic endometrial cancer. Int J Gynecol Cancer 16(3):1370–1373PubMedCrossRef
67.
Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D (2006) HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 16(5):1897–1902PubMedCrossRef
68.
Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM et al (2010) Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 116(1):15–20PubMedCentralPubMedCrossRef
69.
El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M et al (2010) In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer 102(1):134–143PubMedCentralPubMedCrossRef
70.
Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H et al (2012) Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Groupphase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 127(2):345–350PubMedCentralPubMedCrossRef
71.
Schwab CL, English DP, Roque DM, Bellone S et al (2014) Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynec Oncol 135:142–148CrossRef
72.
Oza AM, Elit L, Provencher D et al (2008) A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160 b. J Clin Oncol 26:e5516CrossRef
73.
Rachel RA, Jamal R, Tu D, Walsh W, Dancey J et al (2013) Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer. Gynec Oncol 131:315–320CrossRef
74.
Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE (2013) Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 129:22–27PubMedCrossRef
75.
Boers-Sonderen MJ, Geus-Oei LF, Desar IME, Van der Graaf WTA, Oyen WJG (2014) Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. Target Oncol 9(4):339–347PubMedCrossRef
76.
Fleming GF, Filiaci VL, Marzullo B, Zaino RJ, Davidson AS, Pearl M (2014) Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynec Oncol 132:585–592CrossRef
77.
Colombo N, McMeekin S, Schwartz P et al (2007) A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol 25:5516
78.
Tsoref D, Welch S, Lau S, Biagi J, Tonkin K, Lee Ann Martin LA (2014) Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol 135(2):184–189PubMedCrossRef
79.
Zakikhani M, Blouin MJ, Piura E, Pollak MN (2010) Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123(1):271–279PubMedCrossRef
80.
Ko EM, Walter P, Jackson A, Clarkd L, Franasiak J et al (2014) Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 132:438–442PubMedCrossRef
81.
82.
83.
84.
85.
Ursula M, Ignace V, Floor B, Lainie PM, Scott M, Michael B, Frank C, Yi X, Coumaran E, Sharad G (2014) Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. doi:10.​1016/​j.​ygyno.​2014.​12.​019
86.
National Cancer Institute (2000) Akt Inhibitor MK2206 in treating patients with recurrent or advanced endometrial cancer. In: ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). http://​clinicaltrials.​gov/​show/​NCT01307631 NLM identifier: NCT 01307631
87.
Konecny GE, Kolarova T, O’Brien NA, Winterhoff B, Yang G et al (2013) Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther 12(5):632–642PubMedCrossRef
88.
Gozgit JM, Squillace RM, Wongchenko MJ, Miller D et al (2013) Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol 71:1315–1323PubMedCrossRef
89.
Abstract LBA27—Phase 2 study of second-line dovitinib (TKI258) in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or –non-mutated advanced and/or metastatic endometrial cancer
90.
Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK et al (2014) A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 135:38–43PubMedCentralPubMedCrossRef
91.
Dizon DS, Michael Sill MW, Schilder JM, McGonigle KF, Rahman Z et al (2014) A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynec Oncol 135:441–445CrossRef
92.
Wallin JJ, Edgar KA, Guan J, Berry M, PriorWW Lee L et al (2011) GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 10:2426–2436PubMedCrossRef
93.
Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C et al (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7:1851–1863PubMedCrossRef
94.
Shoji K, Oda K, Nakagawa S, Ikeda Y, Kuramoto H, Nishida M et al (2010) Activity of dual PI3K/mTOR inhibitor, NVP-BEZ235, and mTOR inhibitor, RAD001 (everolimus), in endometrial cancer cell lines [abstract]. J Clin Oncol 28:15s (supp abstr 5074)
95.
96.
Trope C, Johnsson JE, Simonsen E, Christiansen H, Cavallin-Stahl E, Horvath G (1984) Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. Am J Obstet Gynecol 149:379–381PubMedCrossRef
97.
Van Wijk FH, Aapro MS, van Wijk FH, Bolis G et al (2003) Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14:441–448PubMedCrossRef
Metadata
Title
Endometrial cancer: redefining the molecular-targeted approach
Authors
Jesse Lopes da Silva
Eduardo Paulino
Mariane Fontes Dias
Andréia Cristina de Melo
Publication date
01-07-2015
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-015-2758-z

Other articles of this Issue 1/2015

Cancer Chemotherapy and Pharmacology 1/2015 Go to the issue

Original Article

Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial

Original Article

Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy

Original Article

Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with 18F-3′deoxy-3′fluoro-l-thymidine positron emission tomography/computed tomography

Original Article

Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers

Original Article

Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro

Original Article

A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits